PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 19, 2026Cancer Research0 citations

Abstract LB473: JNJ-95437446: Discovery and preclinical characterization of an amivantamab-based EGFR/MET-ADC for solid tumor indications

View Full Paper
BHBenjamin HenleyLCLinxiao ChenMSMegan Siani

Key Points

  • To evaluate the efficacy and safety of JNJ-95437446, an EGFR/MET bispecific antibody drug conjugate.
  • Evaluated JNJ-95437446 in preclinical models of solid tumors including NSCLC, colorectal, and head & neck carcinomas.
  • Assessed pharmacokinetic properties and stability of linker/payload in multiple tests.
  • Conducted safety assessments in GLP NHP studies across various doses.
  • Demonstrated potent, target-dependent cytotoxicity in vitro with rapid internalization.
  • Achieved complete tumor regressions in NSCLC xenograft models resistant to amivantamab.
  • Showed favorable safety profile with strong tolerability in GLP NHP studies.

Abstract

Abstract JNJ-95437446 is a potential best-in-class EGFR/MET bispecific antibody drug conjugate designed to deliver a cytotoxic payload to tumor cells while leveraging the unique characteristics of amivantamab. EGFR and MET are frequently expressed in solid tumors and amivantamab has demonstrated clinical efficacy in multiple non-small cell lung cancer (NSCLC) indications and is being studied in colorectal and head Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts) ; 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86 (8Suppl): Abstract nr LB473.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Henley et al. (2026) studied this question.

synapsesocial.com/papers/69e4745f010ef96374d902b7https://doi.org/10.1158/1538-7445.am2026-lb473
Ask AI
Helpful
Bookmark
Share
View Full Paper